WO2011068404A3 - Administration par inhalation de sel de mésylate de n-(3-éthynylphénylamino)-6,7-bis(2-méthoxyéthoxy)-4-quinazolinamine - Google Patents

Administration par inhalation de sel de mésylate de n-(3-éthynylphénylamino)-6,7-bis(2-méthoxyéthoxy)-4-quinazolinamine Download PDF

Info

Publication number
WO2011068404A3
WO2011068404A3 PCT/NL2010/050810 NL2010050810W WO2011068404A3 WO 2011068404 A3 WO2011068404 A3 WO 2011068404A3 NL 2010050810 W NL2010050810 W NL 2010050810W WO 2011068404 A3 WO2011068404 A3 WO 2011068404A3
Authority
WO
WIPO (PCT)
Prior art keywords
ethynylphenylamino
methoxyethoxy
bis
mesylate salt
inhalation
Prior art date
Application number
PCT/NL2010/050810
Other languages
English (en)
Other versions
WO2011068404A2 (fr
Inventor
Evanthia Dova
Samir Kulkarni
Marcel Hoffmann
Mihaela Maria Pop
Original Assignee
Ultimorphix Technologies B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ultimorphix Technologies B.V. filed Critical Ultimorphix Technologies B.V.
Publication of WO2011068404A2 publication Critical patent/WO2011068404A2/fr
Publication of WO2011068404A3 publication Critical patent/WO2011068404A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une formule pharmaceutique inhalable comprenant le sel de mésylate de la N-(3-éthynylphénylamino)-6,7-bis(2-méthoxyéthoxy)-4-quinazolinamine ainsi que les méthodes de traitement du cancer comprenant l'administration d'une dose thérapeutiquement active à un patient le nécessitant d'une formule pharmaceutique inhalable comprenant le sel de mésylate de la N-(3-éthynylphénylamino)-6,7-bis(2-méthoxyéthoxy)-4-quinazolinamine, le cancer étant choisi dans le groupe constitué par le cancer du poumon non à petites cellules et le carcinome bronchoalvéolaire.
PCT/NL2010/050810 2009-12-02 2010-12-02 Administration par inhalation de sel de mésylate de n-(3-éthynylphénylamino)-6,7-bis(2-méthoxyéthoxy)-4-quinazolinamine WO2011068404A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26589909P 2009-12-02 2009-12-02
US61/265,899 2009-12-02

Publications (2)

Publication Number Publication Date
WO2011068404A2 WO2011068404A2 (fr) 2011-06-09
WO2011068404A3 true WO2011068404A3 (fr) 2012-04-05

Family

ID=43499870

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2010/050810 WO2011068404A2 (fr) 2009-12-02 2010-12-02 Administration par inhalation de sel de mésylate de n-(3-éthynylphénylamino)-6,7-bis(2-méthoxyéthoxy)-4-quinazolinamine

Country Status (1)

Country Link
WO (1) WO2011068404A2 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999055683A1 (fr) * 1998-04-29 1999-11-04 Pfizer Products Inc. Anhydrate et monohydrate de n-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate
US20090048262A1 (en) * 2007-08-17 2009-02-19 Allos Therapeutics, Inc. Combination of 10-propargyl-10-deazaaminopterin and erlotinib for the treatment of non-small cell lung cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU13200A (sh) 1999-03-31 2002-10-18 Pfizer Products Inc. Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999055683A1 (fr) * 1998-04-29 1999-11-04 Pfizer Products Inc. Anhydrate et monohydrate de n-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate
US20090048262A1 (en) * 2007-08-17 2009-02-19 Allos Therapeutics, Inc. Combination of 10-propargyl-10-deazaaminopterin and erlotinib for the treatment of non-small cell lung cancer

Also Published As

Publication number Publication date
WO2011068404A2 (fr) 2011-06-09

Similar Documents

Publication Publication Date Title
IL273194B2 (en) Methods, compounds and preparations for the treatment of parainfluenza virus in patients with a deficiency in the immune system
TR201807411T4 (tr) DNA-PK inhibitörleri.
MX365702B (es) Inhibidores de pirazolil quinoxalina cinasa.
WO2014107740A3 (fr) Méthodes d'inhibition de la prolifération cellulaire et de traitement de certaines maladies
NZ602385A (en) Methods of treating cancer
EA201200618A1 (ru) Производные хроменона с антиопухолевой активностью
JP2011503071A5 (ja) ヨードニトロベンズアミド化合物と抗腫瘍剤の組み合わせによる卵巣がんの治療
EP4324479A3 (fr) Méthodes de traitement ou de prévention de l'asthme par administration d'un antagoniste de l'il-4r
MX2015005798A (es) Terapia de combinacion.
NZ703940A (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
WO2009007749A3 (fr) Composés 947
WO2013021199A3 (fr) Compositions pharmaceutiques
MX2010005631A (es) Nuevos compuestos de hidrocarburo ciclicos para el tratamiento de enfermedades.
WO2012007159A3 (fr) Nouvelles formes médicamenteuses à rétention gastrique
WO2006066074A3 (fr) Medicaments destines au poumon
MX2013012588A (es) Inhibidores de cinasa.
TN2012000566A1 (en) Dry powder formulation comprising an antimuscarinic drug
MX2013002384A (es) Compuestos quinazolina y metodos para utilizarlos.
MD4643C1 (ro) Noi compuşi de indolizină, procedeu de obţinere a lor şi compoziţii farmaceutice care le conţin
WO2014160216A3 (fr) Agents anticancéreux à double ciblage
TN2013000323A1 (en) 9-[4-(3-chlor-2-fluor-phenylamino)-7-methoxy-quinazolin-6-yloxy]-1,4-diaza-spiro[5.5]undecan-5-one dimaleate, use thereof as a drug, and production thereof
JO3434B1 (ar) مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
NZ701261A (en) Novel dosage form and formulation of abediterol
TR201000733A2 (tr) Flutikazon, tiotropyum ve sodyum kromoglikat içeren farmasötik bileşimler.
MX2012013879A (es) Derivados de hidroxipiridona, composiciones farmceuticas de los mismos y su uso terapeutico para tratar enfermedades proliferativas.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10796500

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10796500

Country of ref document: EP

Kind code of ref document: A2